[Translation] A single-center, randomized, open-label, single-dose, two-period, double-crossover bioequivalence study of vemurafenib tablets in healthy subjects under fasting and fed conditions

主要目的：评价健康受试者空腹/餐后单次口服维莫非尼片（240 mg/片）和佐博伏®（参比制剂）（240 mg/片）的药代动力学（PK）行为，评价两种制剂的生物等效性。次要目的：评价健康受试者空腹/餐后口服两种制剂的安全性。

[Translation]

Primary objective: To evaluate the pharmacokinetic (PK) behavior of vemurafenib tablets (240 mg/tablet) and Zelboraf® (reference formulation) (240 mg/tablet) after single oral administration on an empty stomach or after a meal in healthy volunteers, and to assess the bioequivalence of the two formulations. Secondary objective: To evaluate the safety of the two formulations after oral administration on an empty stomach or after a meal in healthy volunteers.

Start Date28 Aug 2025

Sponsor / Collaborator

Shanghai Kezhou Pharmaceutical Co., Ltd.

ChiCTR2500105081

/ Not yet recruitingPhase 4IIT

A prospective, single-arm, open-label exploratory clinical study evaluating the efficacy and safety of the combination therapy of toramatinib, vemurafenib and cetuximab in the first-line treatment of unresectable or advanced BRAF V600E mutant colorectal cancer

Start Date01 Jul 2025

Sponsor / Collaborator

Ruijin Hospital

[+2]

CTR20251251

/ CompletedNot Applicable

评估维莫非尼片与佐博伏®药代动力学的对比研究

[Translation] Comparative study to evaluate the pharmacokinetics of vemurafenib tablets and Zolbovo®

评价健康受试者空腹单次口服维莫非尼片（240 mg/片）和佐博伏®（参比制剂）（240 mg/片）的药代动力学（PK）特征比较。

[Translation]

To evaluate the pharmacokinetic (PK) characteristics of a single fasting oral dose of vemurafenib tablets (240 mg/tablet) and Zelboraf® (reference product) (240 mg/tablet) in healthy subjects.

Start Date16 Apr 2025

Sponsor / Collaborator

Pharmaceutical Biotechnology Qidong Co. Ltd.

100 Clinical Results associated with Vemurafenib

100 Translational Medicine associated with Vemurafenib

100 Patents (Medical) associated with Vemurafenib

3,646

Literatures (Medical) associated with Vemurafenib

01 Apr 2026·Archivos Argentinos de Pediatria

Refractory multisystem Langerhans cell histiocytosis in an infant: use of vemurafenib as a therapeutic option

Article

Author: Caristia, Laura ; Morici, Mercedes ; Mantero, M Natalia ; Della Giovanna, Patricia ; Alfaro, Tatiana ; Venialgo, Gisela ; Tata, M Victoria

Langerhans cell histiocytosis (LCH) is a rare disease that predominantly affects children, characterized by the abnormal clonal proliferation of Langerhans cells with a broad clinical spectrum and prognosis. Refractory LCH to standard treatment usually presents multisystem and risk organs involvement, and mainly affects children under 2 years of age. In these cases, more than half present the BRAF-V600E mutation; detection of this mutation is essential for targeted treatment, such as vemurafenib, a BRAF inhibitor. We present the case of a 6-month-old patient diagnosed with multisystemic LCH without involvement of risk organs, who responded poorly to first- and second-line therapy. A molecular biology study was performed, which reported a BRAF-V600E mutation. Treatment with vemurafenib was indicated, and a good clinical response was obtained after 2 weeks.

01 Dec 2025·Blood Research

Very low-dose vemurafenib maintenance for cardiac Erdheim Chester disease

Letter

Author: Naithani, Rahul ; Rath, P D ; Agrawal, Abhijeet Kumar ; Borah, Pronamee

01 Dec 2025·COMPUTATIONAL BIOLOGY AND CHEMISTRY

Identification of different lung adenocarcinoma subtypes in combination with antidiuretic hormone-related genes and creation of an associated index to predict prognosis and guide immunotherapy

Article

Author: Dai, Hong ; Lv, Yuankai ; Zheng, Hao ; Cai, Xiaoping

BACKGROUND:

Lung adenocarcinoma (LUAD) is one of the most aggressive and rapidly lethal tumor types. Previous studies have demonstrated the involvement of antidiuretic hormone (ADH)-related genes in cancer. However, the role of ADH-related genes in LUAD remains unclear. Therefore, investigating the characteristics of these genes in LUAD is essential.

METHODS:

Differentially expressed genes (DEGs) associated with ADH in LUAD were identified using the STRING database. Consensus clustering was performed, and a protein-protein interaction network was constructed for the DEGs between subtypes. Genes extracted from the PPI network underwent univariate, LASSO, and multivariate Cox regression analyses to develop a predictive model for LUAD. A nomogram integrating clinical data and risk scores was created, and its prognostic power for overall survival (OS) in LUAD patients was evaluated. Additionally, LUAD patients were analyzed for targeted therapies, immune landscape, functional enrichment, and mutation profiles. Finally, qRT-PCR was used to examine the expression of signature genes in LUAD cells.

RESULTS:

Based on ADH-related DEGs, LUAD patients were stratified into two clusters (Cluster 1 and Cluster 2) with distinct survival outcomes. A predictive model incorporating nine feature genes was subsequently constructed using DEGs from these two subtypes. The receiver operating characteristic curve demonstrated the model's prognostic accuracy in predicting OS in LUAD patients. Compared to the high-risk group, patients in the low-risk group exhibited higher immune infiltration levels and immunophenoscore, along with lower tumor immune dysfunction and exclusion scores. Enrichment analysis revealed that immune response pathways and ligand-receptor interactions were the primary functional categories distinguishing the high- and low-risk groups. The low-risk group showed a significantly lower gene mutation burden. Drug sensitivity analysis identified several potential targeted therapies, including Dabrafenib, ARQ-680, Vemurafenib, BGB-283, MLN-2480, and GDC-0994, which might act on hub genes. qRT-PCR validation confirmed that DNAH12 was significantly downregulated in tumor tissues, while DKK1, DLX2, IGFBP1, NTSR1, RPE65, and VGF were markedly upregulated.

CONCLUSION:

This study provided potential prognostic biomarkers for LUAD and might facilitate the development of effective immunotherapy strategies for LUAD patients.

News (Medical) associated with Vemurafenib

30 Sep 2025

·www.einpresswire.com

April - June 2025 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)

Acetaminophen-containing products Anaphylactic reaction FDA is evaluating the need for regulatory action. Aptryxol (desvenlafaxine) DaTscan (ioflupane I 123 injection) Desvenlafaxine extended-release tablets Effexor XR (venlafaxine extended-release) capsules Pristiq (desvenlafaxine) extended-release tablets Venlafaxine (venlafaxine hydrochloride) extended-release tablets False positive radioisotope investigation test result potentially secondary to a drug interaction with venlafaxine FDA is evaluating the need for regulatory action. Barium sulfate-containing products Entero Vu 24% (barium sulfate) oral suspension E-Z-Disk (barium sulfate) tablets Liquid E-Z-Paque (barium sulfate) oral suspension Readi-Cat 2 (barium sulfate) oral suspension Readi-Cat 2 Smoothie (barium sulfate) oral suspension Taglitol V (barium sulfate) oral suspension Varibar Honey (barium sulfate) oral suspension Varibar Nectar (barium sulfate) oral suspension Varibar Pudding (barium sulfate) oral paste Varibar Thin Honey (barium sulfate) oral suspension Varibar Thin Liquid (barium sulfate) oral suspension Anaphylactic reaction FDA is evaluating the need for regulatory action. Blincyto (blinatumomab) for injection Columvi (glofitamab-gxbm) injection Elrexfio (elranatamab-bcmm) injection Epkinly (epcoritamab-bysp) injection Imdelltra (tarlatamab-dlle) for injection Kimmtrak (tebentafusp-tebn) injection Lunsumio (mosunetuzumab-axgb) injection Talvey (talquetamab-tgvs) injection Tecvayli (teclistamab-cqyv) injection Progressive multifocal leukoencephalopathy FDA is evaluating the need for regulatory action. BRAF kinase inhibitors Braftovi (encorafenib) capsules Ojemda (tovorafenib) for oral suspension; tablets Tafinlar (dabrafenib) capsules; tablets Zelboraf (vemurafenib) tablets Gingival hypertrophy FDA is evaluating the need for regulatory action. Briumvi (ublituximab-xiiy) injection Kesimpta (ofatumumab) injection Acute hepatic failure The "Warnings and Precautions" section of the labeling was updated in August 2025 to include information about liver injury. Example: Briumvi labeling Briumvi (ublituximab-xiiy) injection Kesimpta (ofatumumab) injection Ocrevus (ocrelizumab) injection Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) injection Central nervous system infection FDA is evaluating the need for regulatory action. Crexont (carbidopa and levodopa) extended-release capsules Dhivy (carbidopa and levodopa) tablets Duopa (carbidopa and levodopa) enteral suspension Rytary (carbidopa and levodopa) extended-release capsules Sinemet (carbidopa and levodopa) tablets Sinemet CR (carbidopa and levodopa) sustained-release tablets Stalevo (carbidopa, levodopa and entacapone) tablets Vyalev (foscarbidopa and foslevodopa) injection Seizure FDA is evaluating the need for regulatory action. Crysvita (burosumab-twza) injection Hypercalcemia The "Dosage and Administration", "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in August 2025 to include information about hypercalcemia. Crysvita labeling Dexmedetomidine-containing products Dexmedetomidine injection Precedex (dexmedetomidine hydrochloride) injection Igalmi (dexmedetomidine) sublingual film Diabetes insipidus FDA is evaluating the need for regulatory action. Dupixent (dupilumab) injection Ocular infections, irritations, and inflammation FDA is evaluating the need for regulatory action. Eprontia (topiramate) oral solution Qudexy XR (topiramate) extended-release capsules Qsymia (phentermine and topiramate) extended-release capsules Topamax (topiramate) tablets Topamax Sprinkle (topiramate) capsules Trokendi XR (topiramate) extended-release capsules Hypersensitivity FDA is evaluating the need for regulatory action. Gavreto (pralsetinib) capsules Chylothorax FDA is evaluating the need for regulatory action. Glucagon-like peptide-1 (GLP-1) receptor agonists Adlyxin (lixisenatide) injection Bydureon (exenatide) for extended-release injectable suspension Bydureon BCise (exenatide extended-release) injectable suspension Byetta (exenatide) injection Mounjaro (tirzepatide) injection Ozempic (semaglutide) injection Rybelsus (semaglutide) tablets Saxenda (liraglutide) injection Soliqua 100/33 (insulin glargine and lixisenatide) injection Trulicity (dulaglutide) injection Victoza (liraglutide) injection Wegovy (semaglutide) injection Xultophy 100/3.6 (insulin degludec and liraglutide) injection Zepbound (tirzepatide) injection Intestinal obstruction and fecal impaction FDA is evaluating the need for regulatory action. Imbruvica (ibrutinib) capsules; tablets; oral suspension Nail and nail bed conditions (excluding infections and infestations) FDA is evaluating the need for regulatory action. MEK inhibitors Avmapki Fakzynja Co-pack (avutometinib capsules; defactinib tablets) Cotellic (cobimetinib) tablets Mekinist (trametinib) tablets; oral solution Mektovi (binimetinib) tablets Koselugo (selumetinib) capsules Gingival hypertrophy FDA is evaluating the need for regulatory action. Neffy (epinephrine nasal spray) Product storage error FDA is evaluating the need for regulatory action. Nurtec ODT (rimegepant) orally disintegrating tablets Zavzpret (zavegepant) nasal spray Anaphylactic reaction The "Contraindications" and "Warnings and Precautions" sections of the labeling were updated in August 2025 to include information about hypersensitivity reactions, including anaphylaxis. Example: Nurtec ODT labeling Rozlytrek (entrectinib) capsules; oral pellets Brugada syndrome FDA is evaluating the need for regulatory action. Sodium-glucose cotransporter-2 (SGLT2) inhibitors Fournier's gangrene FDA is evaluating the need for regulatory action. Teriparatide injection (a particular generic product) Device malfunction FDA is evaluating the need for regulatory action. Vizamyl (flutemetamol F18 injection) Anaphylactic reaction The "Warnings and Precautions" section of the labeling was updated in June 2025 to include information about anaphylaxis and other serious hypersensitivity reactions. Vizamyl labeling Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug ApprovalBiosimilar

24 Mar 2025

·www.businesswire.com

Vicero Welcomes Renowned Cancer Immunotherapy Experts to its Scientific Advisory Board

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vicero, Inc., a preclinical-stage biopharmaceutical company developing next-generation VINCOBODIES for immune-mediated diseases, today announced the appointment of two distinguished oncologists and immunotherapy experts, Sumit Subudhi, M.D., Ph.D., and Antoni Ribas, M.D., Ph.D., to its Scientific Advisory Board. "We are honored to welcome Dr. Subudhi and Dr. Ribas to our Scientific Advisory Board," said Vikram Kansra, PhD, Founder and Chief Executive Officer of Vicero. "Their pioneering work in cancer immunotherapy and extensive clinical development experience will be invaluable as we advance our VINCOBODY platform, which creates multi-specific molecules designed to overcome the limitations of conventional antibody combinations. Their strategic guidance comes at a pivotal moment in our development as we aim to optimize our bispecific PD-1/CTLA-4 program to deliver potent anti-tumor effects while minimizing immune-related adverse events, ultimately benefiting cancer patients who need better therapeutic options.” Dr. Subudhi is an Associate Professor in the Department of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center. A trained medical oncologist and immunologist, he serves as the principal investigator of multiple biomarker-rich clinical trials evaluating immune checkpoint therapies, bispecific T cell engagers and vaccines. Dr. Subudhi’s translational research focuses on investigating the immunological mechanisms mediating anti-tumor responses and therapy-related toxicities with the ultimate goal of maximizing efficacy and minimizing toxicities for patients with advanced prostate cancer. He also served as lead principal investigator for Prostate Researching Translational Endpoints Correlated to Response (PORTER) clinical trials to inform use of novel combinations, which were sponsored by Parker Institute of Cancer Immunotherapy (PICI) and Cancer Research Institute (CRI). His work has led to the identification of mechanisms associated with resistance to immunotherapies and candidate biomarkers of responses to these approaches. "I am excited to join Vicero's Scientific Advisory Board and provide guidance to the esteemed team in the development of innovative approaches in cancer immunotherapy," said Dr. Subudhi. "The company's novel platform has the potential to address significant unmet needs, particularly in difficult-to-treat cancers where current immunotherapies have shown limited efficacy." Dr. Ribas is professor of medicine, surgery and molecular and medical pharmacology at the University of California Los Angeles (UCLA), director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center and director of the Parker Institute for Cancer Immunotherapy Center at UCLA. He has been instrumental in the clinical development of several FDA-approved agents, including the first anti-PD-1 pembrolizumab (Keytruda), the anti-CTLA-4 tremelimumab (Imjudo) and multiple BRAF and MEK inhibitor combinations. Dr. Ribas is a past president of the American Association for Cancer Research (AACR) and an elected member of the US National Academy of Medicine. Recent work includes laboratory and clinical translational research in adoptive cell transfer therapy with T-cell receptor engineered lymphocytes; examining the antitumor activity of PD-1-blocking antibodies; testing novel targeted therapies blocking oncogenic events in melanoma; and studying primary and acquired resistance to melanoma therapies. Dr. Ribas has been instrumental in the clinical development of several agents approved by the FDA, including the first anti-PD-1 pembrolizumab (Keytruda), the anti-CTLA-4 tremelimumab (Imjudo), two combinations of BRAF and MEK inhibitors vemurafenib (Zelboraf) and cobimetinib (Cotellic), dabrafenib (Tafinlar) and trametinib (Mekinist). He is the recipient of the AACR Richard and Hinda Rosenthal Award, the William B. Coley Award from Cancer Research Institute (CRI), the AACR-CRI Lloyd J. Old Award in Cancer Immunology, two NCI Outstanding Investigator Awards and several other awards, and is a Doctor Honoris Causa from the University of Buenos Aires and the Free University of Brussels. “Vicero's approach to targeting the tumor microenvironment represents a tremendous opportunity to potentially enhance the efficacy of cancer immunotherapies and overcome the longstanding challenges of balancing efficay with safety," said Dr. Ribas. "I’m excited to work with this strong team of highly accomplished drug developers who have already brought many innovative therapies to patients in need and have a genuine commitment to transforming patient care. Vicero’s platform and lead asset hold high promise to overcome limitations in immunotherapy and I’m looking forward to helping finalize the clinical strategy and advance this program into clinic.” About Vicero Vicero is a preclinical biopharmaceutical company pioneering the development of next-generation multivalent VHH VINCOBODIES to conquer unmet medical needs in cancer and immunology. The VINCOBODY product engine is proprietary VHH modular technology that enables Vicero to build best in class IO and ADC therapeutics with the potential to address unmet need in the immuno-oncology solid tumor market. Our team of experienced scientists and drug developers has delivered more than 20 life extending therapies to patients in need. For more information, please visit us at www.vicerobio.com or our LinkedIn page.

Executive ChangeImmunotherapy

15 Oct 2024

·www.biospace.com

CuraSen Therapeutics Appoints Kathleen Sereda Glaub Chief Executive Officer

Expands Adrenergic Pipeline to Address Neurogenic Orthostatic Hypotension and Major Depressive Disorder in Older Adults SAN CARLOS, Calif.--(BUSINESS WIRE)--CuraSen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral, rapid onset, small molecule drugs to treat psychiatric and neurodegenerative diseases, announced today that it has appointed Kathleen Sereda Glaub, MBA, formerly executive chair, as chief executive officer. Dr. Anthony Ford will move to the role of president and chief scientific officer, and continue to lead research and development. Patrick Enright, managing director of Longitude Capital, will become chair of the board. Along with these executive changes, the company announced clinical program updates for its drug candidates that are each designed to restore adrenergic stimulus that declines with age or disease. CuraSen’s most recent development candidate is CuraAX (CST-3056), an alpha-1A adrenoceptor (α 1A -AR) agonist being developed as a treatment for neurogenic orthostatic hypotension (nOH). The company is planning to submit an investigational new drug (IND) application this quarter. A significant orphan indication affecting approximately 120,000-150,000 patients in the U.S., nOH is a dysfunction in the autonomic nervous system common in Parkinson’s disease (PD) and related diseases that causes sudden drops in blood pressure upon standing. This can lead to debilitating dizziness, weakness, cognitive decline and dangerous falls. CuraAX is a selective, CNS-penetrant, α 1A -AR agonist designed to provide cognitive benefit as well as control harmful blood pressure deviations. CuraCN (formerly known as CST-103/CST-107), a beta2 adrenoceptor (β 2 -AR) agonist combination, is targeted for a Phase 2b study in major depressive disorder in adults 65 and older, many of whom also suffer from cognitive decline. These plans are based on the company’s previous Phase 2 clinical study in patients that revealed compelling evidence of anti-depressant efficacy and improvements in cognition tests. CuraXN (formerly known as CST-2032/CST-107), a second β 2 -AR agonist combination, is in development for Alzheimer’s disease (AD) to address both cognitive symptoms and disease progression. All three drug candidates work by restoring adrenergic function that declines with age and, in particular, is lost early in neurodegenerative diseases such as AD & PD. CuraSen’s development candidates have strong potential to improve cognitive function and mood, in addition to addressing specific aspects of disease pathobiology. “We are thrilled to have Ms. Glaub assume the role of chief executive officer as CuraSen seeks to capitalize on the company’s adrenergic platform and clinical data to develop a broad pipeline of drugs for psychiatric and neurodegenerative diseases. These include opportunities for a significant, fast-to-market, orphan opportunity in neurogenic orthostatic hypotension,” said Mr. Enright, board chair. “CuraSen will benefit from the collective and complementary executive experience of both Ms. Glaub and Dr. Ford, both co-founders of the company.” Ms. Glaub brings more than 30 years of experience in biopharmaceutical corporate development, strategy, financing and company-building. She serves on the board of directors of IO Biotech, and previously served on the boards of Codexis, Aligos Pharmaceuticals and Escient Pharmaceuticals. Ms. Glaub was previously chief executive officer of Afferent Pharmaceuticals, which was acquired by Merck in 2016 for $1.25 billion. Under her leadership, the company advanced gefapixant to Phase 3 readiness for the treatment of chronic cough and raised $80 million in additional private funding for Afferent. Previously, she served as president of Plexxikon, and helped develop two FDA-approved drugs, Zelboraf® for metastatic melanoma and Turalio® for tenosynovial giant cell tumor (TGCT). She led Plexxikon’s business and financing strategy, negotiated multimillion-dollar partnerships, and led the sale of the company to Daiichi Sankyo for nearly $1 billion. She previously held positions as senior vice president and chief financial officer of Cell Genesys, treasurer of Genentech, and various finance and treasury roles with Intel Corporation. Ms. Glaub received her BA from the University of California, Berkeley, and her MBA from Northwestern University. “CuraSen’s expertise in adrenergic pharmacology, chemistry and clinical development has led to the discovery of three promising drug candidates focused on some of the most debilitating and common neurodegenerative and psychiatric diseases affecting patients and their families. Our adrenergic target mechanisms are already validated by approved drugs in a range of indications, and we have confirmed the ability to develop CNS-penetrant compounds with a unique approach to safety,” said Glaub. “Given the strong and rapid-onset efficacy signals pointing to an anti-depressant effect in our past studies and our understanding of adrenergic deficits in older adults, we believe there is a unique opportunity to address depression in these patients with CuraCN. With CuraXN, we hope to deliver a transformational treatment for Alzheimer’s disease with our holistic approach to restoring brain functionality and health. Lastly, with CuraAX, we believe we can offer major advantages over current treatments for nOH, including durability of efficacy and cognitive benefit, dosing convenience and improved safety.” About CuraSen Therapeutics CuraSen is focused on the development of new treatments for psychiatric and neurodegenerative diseases, including neurogenic orthostatic hypotension, major depressive disorder and Alzheimer’s disease. CuraSen’s drugs are small molecule, oral tablets designed to activate certain receptor populations in the brain to compensate for decline of the adrenergic system driven by aging and disease. The company has evaluated two β 2 -AR agonist candidates, CuraCN and CuraXN, in multiple Phase 2 clinical studies for effects on memory, attention, executive function and mood, as well as safety and tolerability. CuraSen is planning to submit an IND application by the end of 2024 for its third drug candidate CuraAX, an α 1A -AR agonist, for the treatment of nOH. For more information, please visit . Contacts Susan Kinkead Kinkead Communications susan@kinkeadcomm.com 415-509-3610

Phase 2Executive ChangeAcquisition

100 Deals associated with Vemurafenib

External Link

KEGG	Wiki	ATC	Drug Bank
D09996	Vemurafenib	L01XE15	DB08881

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
BRAF mutation positive Melanoma	Japan	Chugai Pharmaceutical Co., Ltd.	26 Dec 2014
BRAF V600 mutation-positive Melanoma	European Union	Roche Registration GmbH	17 Feb 2012
BRAF V600 mutation-positive Melanoma	Iceland	Roche Registration GmbH	17 Feb 2012
BRAF V600 mutation-positive Melanoma	Liechtenstein	Roche Registration GmbH	17 Feb 2012
BRAF V600 mutation-positive Melanoma	Norway	Roche Registration GmbH	17 Feb 2012
Melanoma	United States	Hoffmann-La Roche, Inc.	17 Aug 2011

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
BRAF V600E mutant Colorectal Cancer	Phase 3	China	-	25 Oct 2023
Anaplastic Thyroid Carcinoma	Phase 3	United Kingdom	-	01 Mar 2023
BRAF V600 mutation-positive Neoplasms	Phase 3	United Kingdom	-	01 Mar 2023
Colorectal Cancer	Phase 3	United Kingdom	-	01 Mar 2023
Erdheim-Chester Disease	Phase 3	United Kingdom	-	01 Mar 2023
Glioma	Phase 3	United Kingdom	-	01 Mar 2023
Hematologic Neoplasms	Phase 3	United Kingdom	-	01 Mar 2023
Laryngeal Neoplasms	Phase 3	United Kingdom	-	01 Mar 2023
Multiple Myeloma	Phase 3	United Kingdom	-	01 Mar 2023
Non-Small Cell Lung Cancer	Phase 3	United Kingdom	-	01 Mar 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02414750 (Pubmed \| EJNMMI Res)	Phase 2	Melanoma, Cutaneous Malignant	75	Vemurafenib/Cobimetinib	qgtxnzvxfl(pakirkoecz) = elxdsmxlvh dtmmxvlhqu (yikrcsexvz, 0 - 1897) View more	Positive	28 May 2025
NCT03554083 (NeoACTIVATE, Pubmed \| J Immunother Cancer)	Phase 2	Melanoma Neoadjuvant gut microbiome signals \| peripheral blood immune subsets	-	Neoadjuvant cobimetinib, atezolizumab, vemurafenib	hopvwhkfnv(vzaxgwynoq) = uqgpkaqlkn oymllxicbi (ngwoisjame )	-	01 Apr 2025
				Neoadjuvant cobimetinib, atezolizumab	hopvwhkfnv(vzaxgwynoq) = ulrvzudknj oymllxicbi (ngwoisjame )
NCT04462471 (CTgov)	Phase 1	Thyroid Cancer, Follicular \| Papillary thyroid cancer \| Refractory Thyroid Gland Carcinoma	8	Copanlisib+Vemurafenib (Dose Level 1)	bkphyfjqrv = ijuoamxdvu mpwuctjjgc (tmjjyulakw, hicxyowldm - ptdgznvewo) View more	-	28 Feb 2025
				Copanlisib+Vemurafenib (Dose Level 2)	bkphyfjqrv = surahaxypq mpwuctjjgc (tmjjyulakw, quwbfspton - jdaiptaibd) View more
NCT03181100 (Pubmed \| JAMA Oncol)	Phase 2	Anaplastic Thyroid Carcinoma \| thyroid gland poorly differentiated carcinoma \| Metastatic Thyroid Gland Carcinoma BRAF V600E \| NF1/2	43	Vemurafenib/Cobimetinib + Atezolizumab	nomzapjayr(fhsqkmvznl) = seoqniamkz jceoncmlfs (hlrpbkyycn, 16 - NE) View more	Positive	01 Dec 2024
				Cobimetinib + Atezolizumab	nomzapjayr(fhsqkmvznl) = wktebfcbsc jceoncmlfs (hlrpbkyycn, 5.1 - 37.0) View more
ACTRN12620000861954 (MoST, ESMO2024) Manual	Phase 2	BRAF mutation Solid Tumors \| BRAF V600 Mutation-Positive Non-small Cell Lung Cancer First line BRAF V600M	64	vemurafenib cobimetinib	qmhqyhawun(ccfzeroksi) = stbqqctvwv uunpnukzwv (jvumabwtbz ) View more	Positive	14 Sep 2024
				vemurafenib cobimetinib	qmhqyhawun(ccfzeroksi) = chpgwdcxsn uunpnukzwv (jvumabwtbz ) View more
NCT02091141 (MyPathway, CTgov)	Phase 2	Advanced Malignant Solid Neoplasm \| Bladder Cancer \| Biliary Tract Neoplasms ... View more	673	Trastuzumab+Pertuzumab (Trastuzumab Plus Pertuzumab)	epudccuixd = oarppmbwnz nhunmlnpvy (kcdgvqjkgl, sgylcvhrrd - ddjdigxptk) View more	-	23 Jul 2024
				Atezolizumab (Atezolizumab)	epudccuixd = skdgeltoox nhunmlnpvy (kcdgvqjkgl, rkocbqgbyc - tirpepjnmx) View more
NCT03781219 (Pubmed) Manual	Phase 1	BRAF mutation Solid Tumors BRAF V600	72	Tunlametinib 9 mg Vemurafenibfenib 720 mg	dffcreikrs(ylworzlymx) = All 72 patients had treatment-related adverse events (TRAEs) idkfwuewgy (ehgvpxeotc ) View more	Positive	12 Jun 2024
				Tunlametinib 9 mg plus Vemurafenib 720 mg (RP2D)
NCT03625141 (TRICOTEL, ASCO2024) Manual	Phase 2	BRAF V600 mutation-positive Melanoma BRAF V600 mutation	65	Atezolizumab (A) + cobimetinib (C) + vemurafenib (V)	zheioofsju(lrliefjzcl) = smqsppkdoi oufbqfevqs (jgxbcvliba, 27 - 51) View more	Positive	24 May 2024
NCT05263453 (ASCO2024) Manual	Phase 2	BRAF V600 mutation-positive Melanoma BRAF V600-mutant	17	Tunlametinib 9 vemurafenib	ytppewtkff(fslvbwcxop) = wmiismeknm sioodvrdhg (iklfkxbgwl, 44.0 - 89.7) View more	Positive	24 May 2024
				Tunlametinib + vemurafenib (pre-treated pts)	ytppewtkff(fslvbwcxop) = jivngslllb sioodvrdhg (iklfkxbgwl, 46.2 - 95.0) View more
EUCTR2017-001836-20-IT (HCL-PG04, EHA 12024 \| EHA 22024) Manual	Phase 2	Hairy Cell Leukemia BRAF V600E	26	Obinutuzumab +/- VEMURAFENIBVEMURAFENIB	jntdhlxyvv(jlyeppgdog) = gqroogedjw sfzvfikpzt (hnpgyndndp ) View more	Positive	14 May 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis